Welcome to our dedicated page for X4 Pharmaceuticals news (Ticker: XFOR), a resource for investors and traders seeking the latest updates and insights on X4 Pharmaceuticals stock.
X4 Pharmaceuticals Inc (XFOR) is a clinical-stage biopharmaceutical company pioneering oral therapies targeting the CXCR4 pathway to treat rare immunodeficiency disorders. This page provides a centralized hub for all official news, including press releases, clinical trial updates, and regulatory developments.
Investors and researchers will find timely updates on mavorixafor’s progress, partnership announcements, and financial disclosures. Content categories include clinical trial milestones, regulatory submissions, strategic collaborations, and earnings reports, ensuring comprehensive coverage of XFOR’s advancements.
Bookmark this page to stay informed about X4 Pharmaceuticals’ innovations in rare disease therapeutics, designed to address unmet medical needs through precision immunology.
X4 Pharmaceuticals (Nasdaq: XFOR) announced a poster presentation at the AACR Annual Meeting 2022 in New Orleans, from April 8-12, 2022. The poster, titled Mavorixafor Enhances Efficacy of Bruton’s Tyrosine Kinase Inhibitors, will detail mavorixafor’s role in overcoming bone marrow stroma protections in Waldenström’s macroglobulinemia. Presenter Chi Nguyen, Ph.D., will share insights on April 10, 1:30-5 pm CT. Mavorixafor, a leading small molecule therapy, targets CXCR4 and is critical to treating immune system diseases, including WHIM syndrome.
X4 Pharmaceuticals (Nasdaq: XFOR) announced presentations at two upcoming virtual healthcare conferences. The company will present a corporate overview at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 3:45 PM ET. Additionally, a fireside chat will occur at the Canaccord Genuity 2022 Horizons in Oncology Virtual Conference on April 14, 2022, from 10:30 AM to 11:00 AM ET. Both events will be available for live streaming and archived on X4's website for 90 days.
X4 Pharmaceuticals (NASDAQ: XFOR) announced on March 31, 2022, that its Board's Compensation Committee issued inducement awards to new employees under the 2019 Inducement Equity Incentive Plan. The inducement awards include options for 92,850 shares of common stock at an exercise price of $1.75, equivalent to the stock's closing price on the grant date. These options vest over four years, contingent on ongoing employment. X4 specializes in CXCR4-targeted therapies aimed at treating immune system disorders, with its lead candidate being mavorixafor, currently in clinical trials.
X4 Pharmaceuticals (Nasdaq: XFOR) announced its fourth-quarter and annual financial results for 2021, reporting a net loss of $30.2 million for Q4 and $88.7 million for the year. Despite increased losses compared to 2020, the company completed enrollment in its pivotal 4WHIM Phase 3 trial for mavorixafor, targeting WHIM syndrome, with top-line data expected in 4Q22. Ongoing trials for chronic neutropenia and Waldenström’s macroglobulinemia are on track, with additional data anticipated in 2022. As of December 31, 2021, X4 had $83.1 million in cash, projected to fund operations into late 2022.
X4 Pharmaceuticals (Nasdaq: XFOR) will report its Q4 2021 financial results and recent business highlights on March 17, 2022. The company will host a conference call at 8:30 a.m. ET on the same day, accessible via phone or webcast. X4 specializes in developing CXCR4-targeted therapeutics, with its lead candidate, mavorixafor, showing potential in treating immune disorders and certain cancers. Mavorixafor is currently in various clinical trials, including a fully enrolled Phase 3 trial for WHIM syndrome, showcasing the drug's promising efficacy and safety profile.
X4 Pharmaceuticals (Nasdaq: XFOR) is set to engage in high-profile discussions at two upcoming healthcare conferences. The company will participate in the 42nd Annual Cowen Healthcare Conference on March 7, 2022, focusing on a Non-Malignant Hematology Panel at 12:50 PM ET. Additionally, they will host a Fireside Chat at the 32nd Annual Oppenheimer Healthcare Conference on March 15, 2022, at 4:00 PM ET. Live webcasts will be available on their website, with recordings accessible for 90 days post-event.
X4 Pharmaceuticals (Nasdaq: XFOR) announced on March 1, 2022, that its Compensation Committee granted inducement awards to new employees under its 2019 Inducement Equity Incentive Plan. This includes options to purchase 22,250 shares and restricted stock units for 3,500 shares. The options have a ten-year term with an exercise price of $1.50 per share, vesting over four years. X4 focuses on developing novel therapies for immune system dysfunction, with its lead candidate mavorixafor currently in global Phase 3 trials and addressing rare diseases like WHIM syndrome.
X4 Pharmaceuticals (XFOR) announced the issuance of inducement awards to new employees as part of its 2019 Inducement Equity Incentive Plan. On January 31, 2022, the Compensation Committee granted options to purchase 33,000 shares and restricted stock units covering 11,000 shares of common stock. The options have a ten-year term with an exercise price of $2.06, vesting over four years. X4 is developing novel therapies for immune dysfunction, with its lead candidate, mavorixafor, undergoing Phase 3 trials for WHIM syndrome.
X4 Pharmaceuticals, a leader in immune system therapeutics, will participate in a fireside chat at the B. Riley Securities Oncology Investor Conference on January 28, 2022, at 1:00 PM ET. The conference will focus on their innovative therapies, including the lead candidate mavorixafor, a novel CXCR4-targeted small molecule. A live webcast will be available on their website, where it will remain archived for 30 days post-event. X4 Pharmaceuticals is dedicated to advancing treatments for various immune system dysfunctions and has ongoing clinical trials for its lead candidate.
Sporos Bioventures has announced the formation of a Strategic Advisory Board (SAB), chaired by Douglas E. Williams, Ph.D. The inaugural members include leading experts in precision oncology and immunology: Keith T. Flaherty, M.D., Bing Yao, Ph.D., and Douglas Hanahan, Ph.D. The SAB will support Sporos in advancing its research portfolio targeting unmet medical needs in cancer and immune diseases. This initiative reflects the company's commitment to innovation and collaboration in drug development.
